Cardiff Oncology, Inc. (CRDF) Financial Analysis & Valuation | Quarter Chart
Cardiff Oncology, Inc. (CRDF)
CRDFPrice: $1.98
Fair Value: 🔒
🔒score
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase ... more
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer pa... more
Description
Shares
| Market Cap | $133.10M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Mani Mohindru |
| IPO Date | 2004-07-27 | CAGR | — |
| Employees | 32 | Website | www.cardiffoncology.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
CRDF chart loading...
Fundamentals
Technicals
| Enterprise Value | $171.19M | P/E Ratio | -3.76 |
| Forward P/E | -2.4 | PEG Ratio | — |
| P/S Ratio | 290.57 | P/B Ratio | 2.92 |
| P/CF Ratio | -3.49 | P/FCF Ratio | -3.51 |
| EPS | $-0.79 | EPS Growth 1Y | -21.43% |
| EPS Growth 3Y | -10.47% | EPS Growth 5Y | -33.62% |
| Revenue Growth 1Y | -32.89% | Gross Margin | -24.23% |
| Operating Margin | -106.67% | Profit Margin | -99.9% |
| ROE | -0.82% | ROA | -0.74% |
| ROCE | -1.08% | Current Ratio | 3.67 |
| Quick Ratio | 3.67 | Cash Ratio | 1.07 |
| Debt/Equity | 0.02 | Interest Coverage | — |
| Altman Z Score | -6.61 | Piotroski Score | 1 |